Sunkyu Kim

发表

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

K. Cole, G. Caponigro, P. Raman, 2016, Clinical Cancer Research.

Cloning, expression, and characterization of a soluble calcium-activated nucleotidase, a human enzyme belonging to a new family of extracellular nucleotidases.

Thomas M. Smith, T. Kirley, Sunkyu Kim, 2002, Archives of biochemistry and biophysics.

Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.

F. Lombardo, Alice T. Loo, L. Hamann, 2017, Journal of medicinal chemistry.

Cancer Therapy : Preclinical Dual CDK 4 / CDK 6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

K. Cole, G. Caponigro, J. Maris, 2013 .

Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.

F. Lombardo, L. Hamann, T. Abrams, 2018, Journal of medicinal chemistry.

Molecular basis of USP7 inhibition by selective small-molecule inhibitors

Elizabeth C. Townsend, Claire Heride, D. Komander, 2017, Nature.

Discovery of 5,7-Dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-ones as Highly Selective CDK2 Inhibitors.

Yvonne Lo, M. Covington, S. Diamond, 2022, ACS medicinal chemistry letters.

Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma

B. Weir, B. Crompton, K. Stegmaier, 2015, Oncotarget.

Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.

W. Sellers, G. Caponigro, Alice T. Loo, 2013 .

4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.

Rajiv Chopra, Sunkyu Kim, Ming Xu, 2010, Journal of medicinal chemistry.

Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma

G. Caponigro, Nanxin Li, Jennifer L. Harris, 2016, Clinical Cancer Research.

The Discovery of Kisqali ® (Ribociclib): A CDK 4/6 Inhibitor for the Treatment of HR +/ HER 2− Advanced Breast Cancer

R. Chopra, Sunkyu Kim, C. Brain, 2021 .

Cyclin C is a haploinsufficient tumour suppressor

Na Li, Iannis Aifantis, Jon C. Aster, 2014, Nature Cell Biology.

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

Andrew C. Wood, Daniel Martinez, Sharon J. Diskin, 2013, Clinical Cancer Research.

Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.

Paul N. Mortenson, M. Congreve, R. Cheng, 2012, ACS medicinal chemistry letters.

Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo

G. Demetri, Alice T. Loo, A. Kung, 2014, Molecular Cancer Therapeutics.

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

W. Sellers, G. Caponigro, Alice T. Loo, 2018, Oncotarget.

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Joshua M. Korn, Ping Zhu, Sunkyu Kim, 2013, Cancer discovery.

Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc*

C. Dang, D. Wonsey, R. Reddy, 2000, The Journal of Biological Chemistry.

Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

K. Stegmaier, M. Harris, G. Alexe, 2015, Clinical Cancer Research.

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.

J. Lehár, Manway Liu, R. Schlegel, 2014, Cancer cell.

Validating cancer drug targets

Sunkyu Kim, J. D. Benson, William R. Sellers, 2006, Nature.

Small Molecule Therapeutics Antiproliferative Effects of CDK 4 / 6 Inhibition in CDK 4-Ampli fi ed Human Liposarcoma In Vitro and In Vivo

G. Demetri, Alice T. Loo, A. Kung, 2014 .

Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

Joshua M. Korn, Tara L. Naylor, Michael P. Morrissey, 2013, Nature Medicine.

An F 876 L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV 3100 ( Enzalutamide )

Joshua M. Korn, W. Sellers, J. Korn, 2013 .

Depletion of methionine aminopeptidase 2 does not alter cell response to fumagillin or bengamides.

M. Sabio, K. Lamontagne, R. Versace, 2004, Cancer research.

Proteomics-based Target Identification

Sunkyu Kim, Hans Voshol, J. Decaprio, 2003, Journal of Biological Chemistry.

USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma

Andreas C. Damianou, A. Damianou, Claire Heride, 2020, bioRxiv.

The deubiquitylase USP9X controls ribosomal stalling

Claire Heride, D. Komander, A. Behrens, 2020, bioRxiv.

Multiple Subtypes of Phospholipase C Are Encoded by the norpA Gene of Drosophila melanogaster(*)

R D Shortridge, S Kim, R R McKay, 1995, The Journal of Biological Chemistry.

Function of the c-Myc oncogenic transcription factor.

K. Zeller, C. Dang, Q. Li, 1999, Experimental cell research.

c-Myc suppresses the tumorigenicity of lung cancer cells and down-regulates vascular endothelial growth factor expression.

E. Gabrielson, G. Diette, C. Dang, 2000, Cancer research.

Identification of c-myc responsive genes using rat cDNA microarray.

N. Lee, E. Liu, C. Dang, 2000, Cancer research.

Phospholipase C Rescues Visual Defect in norpA Mutant of Drosophila melanogaster(*)

W. Stark, R. R. McKay, Sunkyu Kim, 1995, The Journal of Biological Chemistry.

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

K. Cole, G. Caponigro, J. Maris, 2013, Clinical Cancer Research.

Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo

G. Demetri, Alice T. Loo, A. Kung, 2014, Molecular Cancer Therapeutics.

deletion and small molecule inhibition destabilises c-MYC and elicits 1 regression of squamous cell lung carcinoma 2 3

Kearns, Andreas C. Damianou, D. Komander, 2022 .